Categories
Credit Cards

Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is roughly 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the first quarter of 2021.

The current consensus among eleven TipRanks analysts is actually for a moderate Buy rating of shares in CVS Health, with an average price goal of eighty four dolars.

The analysts price targets range from a high of hundred one dolars to a low of $61.

In the latest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management strategies. The retail or Long Term Care segment has offering of prescribed drugs as well as assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products and associated services, which includes medical, pharmacy, dental, behavioural health, medical management abilities. The Corporate segment involves in providing administrative services and management. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *